Written By: Biopharma Informatic Team
Houston, TX — March 2026 — Every so often, there's a conference that genuinely deserves the word "landmark”. The World Vaccine Congress in Washington D.C. is one of them. Running March 30 through April 2 at the Walter E. Washington Convention Center, this four-day event brings together the minds behind the future of vaccines including scientists, developers, policymakers, and researchers all under one roof. And Biopharma Informatic will be right there in the mix.
Since 2000, the World Vaccine Congress has grown into the single largest gathering dedicated to vaccines in the world. This year's edition is expected to draw 2,800+ attendees, 550+ speakers, and 300+ exhibitors across topics that span the entire vaccine process, from infectious disease and cancer immunotherapy to clinical development, manufacturing, safety, supply chain, and market access.
Founded in 2010, Biopharma Informatic has spent over a decade building the kind of clinical research infrastructure that makes trials actually work. As a Site Management Organization, we sit at the intersection of pharmaceutical sponsors, CROs, and investigative sites, handling everything from feasibility and startup to study closeout. Our network spans 100+ investigators across 7 states and 30+ active research centers, and our sponsor partnerships include Janssen, Eli Lilly, and Novo Nordisk, among others.
Vaccine trials are an important part of the work we do. At Biopharma Informatic, our ongoing pneumococcal vaccine study helps researchers better understand how vaccines can protect people from serious infections. These efforts contribute to broader public health goals by supporting studies that strengthen prevention. Attending the World Vaccine Congress helps us stay connected to the science, the people, and the progress that allows us to do this work better.
Here's something worth saying plainly: a vaccine is only as good as the population it was tested in. Immune responses differ. Health histories differ. Communities carry different risk profiles. When clinical trials lack diversity in race, ethnicity, age, background, the data gets thinner than it should be, and ultimately so does the protection the vaccine offers.
At Biopharma Informatic, our sites are embedded in some of the most diverse communities in the country. That's not a talking point, it's a structural advantage we work hard to maintain, because we believe representative research is the foundation of medicine people can actually trust.
"The World Vaccine Congress brings together exactly the kind of minds this moment calls for," said Shuja Naqvi, CEO of Biopharma Informatic. "Vaccines sit at the intersection of science, public trust, global health and getting it right requires collaboration across every part of the research chain. We're going to Washington to be part of that dialogue, and to bring back everything we learn to the work we do every day."
Biopharma Informatic will be represented at WVC 2026 by:
Shuja Naqvi Chief Executive Officer
If you're at the Congress and want to talk about trials, sites, or about building research that actually reflects the world, we're easy to find and always up for a good conversation. No pitch decks required.
Biopharma Informatic is a Houston-based Site Management Organization connecting sponsors and CROs with experienced investigators across multiple therapeutic areas. With 100+ investigators, 30+ active research centers, and a genuine commitment to inclusive, high-quality research, we support clinical trials from the first patient into the final report.
For more information, visit www.biopharmainfo.net